BOBULSKY SUSAN sold $11K of ADPT
BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 487 shares of Adaptive Biotechnologies Corp (ADPT) at $22.00 on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size ($10,714 total) and that it was executed under a pre-arranged Rule 10b5-1 plan; no new company performance information is provided.
Market read
Primarily a compliance/positioning datapoint; not a fundamental catalyst.
What to watch
The disclosure lacks context on total planned sales, tax/portfolio needs, and whether other insiders are selling/buying concurrently.
Background
This is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies’ Chief Commercial Officer (MRD).
Ticker impact
Adaptive Biotechnologies Form 4 shows CCO Susan Bobulsky sold 487 shares at $22 on 2026-07-01 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this disclosure.
The filing is a small, pre-arranged open-market sale by an officer; it does not include new operating, regulatory, or financial guidance.
Market effects
No clear sector read-through from a single officer’s small 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Even 10b5-1 sales can coincide with internal views on near-term risk, so some traders may briefly fade/trim risk around the filing date.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider transaction disclosure (ADPT).
- insiderBOBULSKY SUSAN
Chief Commercial Officer (MRD) who sold 487 shares under a 10b5-1 plan.